RA response to treatment has been improved extensively since the introduction of DMARDs.[21,22] Although we confirm this, it is reasonable to consider the impact of reporting limit of CRP on the calculation of DAS28 and evaluating response to treatment, since reporting lower values of CRP by new methods or reducing the lower limit of CRP will cause lower DAS28 implying better response to treatment. Here, CRP is linked to rheumatoid arthritis.